Valiant Laboratories Ltd
NSE: VALIANTLAB BSE: 543998
₹125.08
(0.91%)
Sun, 11 Oct 2026, 11:11 pm
Market Cap (in Cr)663.16
PE Ratio42.40
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KValiant Laboratories Cashflow
| Particulars | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Deprecation and amortization | -26.07M | -24.90M | -15.63M | -19.66M | -20.93M |
| Accumulated depreciation, total | -49.77M | -69.96M | -174.92M | -192.67M | -211.23M |
| Cash from operating activities | 75.10M | 14.44M | 560.52M | 18.08M | 13.14M |
| Funds from operations | 331.70M | 296.86M | 308.93M | 21.78M | 50.66M |
| Net income (cash flow) | 305.93M | 274.96M | 289.98M | 3.20M | -22.01M |
| Depreciation & amortization (cash flow) | 26.07M | 24.90M | 15.63M | 19.66M | 20.93M |
| Depreciation/depletion | 26.07M | 24.90M | 15.63M | 19.66M | 20.62M |
| Amortization | — | — | — | — | 302.00K |
| Deferred taxes (cash flow) | 0 | 0 | 0 | 0 | 0 |
| Non-cash items | -164.60M | -145.08M | -88.06M | 9.82M | 44.86M |
| Changes in working capital | -256.60M | -282.42M | 251.59M | -3.70M | -37.52M |
| Cash from investing activities | -166.69M | -122.38M | -551.94M | -1.44B | -527.68M |
| Capital expenditures | -16.69M | -68.76M | -414.98M | -458.70M | -1.14B |
| Capital expenditures - fixed assets | -16.69M | -68.76M | -414.98M | -458.70M | -1.14B |
| Capital expenditures - other assets | — | — | 0 | 0 | — |
| Cash from financing activities | 130.29M | 69.88M | -9.09M | 1.53B | 446.52M |
| Free cash flow | 58.41M | -54.32M | 145.54M | -440.63M | -1.13B |
